NASDAQ · IMCR
Immunocore Holdings plc
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IMCR: Nov 5, 2026
Immunocore Holdings plc American Depositary Shares is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.11. The reported EPS for the same quarter last year was $0.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.11 | $-0.06 | $-0.20 | 5 |
| Dec 2026 | $-0.11 | $0.01 | $-0.40 | 5 |
| Mar 2027 | $0.04 | $0.18 | $-0.15 | 3 |
| Jun 2027 | $0.14 | $0.29 | $-0.11 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · MarketBeat- Zacks · Sep 15, 11:22 AM EDTImmunocore Hits Enrollment Target in Kimmtrak Label Expansion StudyIMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.
- Zacks · Aug 25, 11:07 AM EDTWill Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?Strong demand for Kimmtrak is fueling Immunocore's growth, while potential label expansion and late-2026 data could add further upside.
- Zacks · Aug 10, 12:16 PM EDTIMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More MomentumImmunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.
- Zacks · Aug 10, 11:41 AM EDTIs IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.
- Zacks · Aug 10, 11:39 AM EDTIMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS MissImmunocore's Q2 revenue beat reflects strong Kimmtrak demand, but an EPS miss and distributor stocking headwind cloud the near-term outlook.
- Zacks · Aug 7, 1:27 PM EDTImmunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y RevenuesIMCR incurs wider-than-expected Q2 loss. However, revenues beat as sole drug Kimmtrak sales rise 18.3% year over year on higher U.S. and international sales.
- Zacks · Aug 7, 9:55 AM EDTWall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High?The average of price targets set by Wall Street analysts indicates a potential upside of 77.9% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- MarketBeat · Aug 6, 3:04 PM EDTImmunocore Q2 Earnings Call HighlightsGrowth Picks: 3 Low-Cost Stocks That Could Double in ValueImmunocore (NASDAQ:IMCR) reported continued growth for KIMMTRAK in the second quarter and first half of 2026, while advancing three late-stage melanoma trials and early-stage programs in oncology, HIV and Type 1 diabetes.
- Zacks · Jul 27, 11:54 AM EDTHow Immunocore Is Expanding Beyond Its Rare-Cancer Drug KimmtrakKimmtrak anchors IMCR today, but its broader T-cell receptor platform is targeting larger cancer, infectious disease and autoimmune markets.
- Zacks · Jul 27, 11:53 AM EDTIs Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?Kimmtrak's sales growth supports IMCR, but premium valuation and reliance on one product keep investors focused on upcoming pipeline catalysts.
- Zacks · Jul 27, 11:51 AM EDTImmunocore's Kimmtrak Growth Story and Major 2026 Catalysts AheadIMCR's Kimmtrak sales climbed 29% in 2025 on wider adoption, with pivotal 2026 trial results set to test its next expansion opportunity.
- Zacks · Jul 7, 11:12 AM EDTEU Approves Expanded Use of ABBV's Tepkinly in Follicular LymphomaAbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Immunocore Holdings plc from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.